Abstract
AbstractBackgroundBlood‐based markers (BBMs) have recently showed promise to revolutionize the diagnostic and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of interventional trials.MethodHere we discuss in detail further research needed to be performed before widespread use of BBMs.ResultWe already now recommend use of BBMs as (pre‐)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease‐modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work‐up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand‐alone diagnostic AD markers, or before considering use in primary care.ConclusionWe recommend use of AD‐associated BBMs as (pre‐)screeners in trials and cautious introduction of BBMs in clinical practice, provided AD status in confirmed whenever possible using CSF or PET. We summarize prioritized research needed to be performed before widespread use of AD‐associated BBMs in clinical trials and practice, including different types of preanalytical, analytical and real‐world clinical studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.